Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Serum endocan as a survival predictor for patients with liver cirrhosis.

Toshikuni N, Ozaki K, George J, Tsutsumi M.

Can J Gastroenterol Hepatol. 2015 Nov-Dec;29(8):427-30.

2.

Serum proteoglycans as prognostic biomarkers of hepatocellular carcinoma in patients with alcoholic cirrhosis.

Nault JC, Guyot E, Laguillier C, Chevret S, Ganne-Carrie N, N'Kontchou G, Beaugrand M, Seror O, Trinchet JC, Coelho J, Lasalle P, Charnaux N, Delehedde M, Sutton A, Nahon P.

Cancer Epidemiol Biomarkers Prev. 2013 Aug;22(8):1343-52. doi: 10.1158/1055-9965.EPI-13-0179. Epub 2013 Jun 18.

3.

King's score as a novel prognostic model for patients with hepatitis B-associated hepatocellular carcinoma.

Pang Q, Bi JB, Xu XS, Liu SS, Zhang JY, Zhou YY, Qu K, Liu C.

Eur J Gastroenterol Hepatol. 2015 Nov;27(11):1337-46. doi: 10.1097/MEG.0000000000000452.

PMID:
26275082
4.

Comparison of outcomes between patients with alcoholic cirrhosis and those with hepatitis C virus-related cirrhosis.

Toshikuni N, Izumi A, Nishino K, Inada N, Sakanoue R, Yamato R, Suehiro M, Kawanaka M, Yamada G.

J Gastroenterol Hepatol. 2009 Jul;24(7):1276-83. doi: 10.1111/j.1440-1746.2009.05851.x. Epub 2009 Apr 6.

PMID:
19486451
5.

Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.

Meguro M, Mizuguchi T, Nishidate T, Okita K, Ishii M, Ota S, Ueki T, Akizuki E, Hirata K.

World J Gastroenterol. 2015 Apr 28;21(16):4933-45. doi: 10.3748/wjg.v21.i16.4933.

6.

Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis.

N'Kontchou G, Paries J, Htar MT, Ganne-Carrie N, Costentin L, Grando-Lemaire V, Trinchet JC, Beaugrand M.

Clin Gastroenterol Hepatol. 2006 Aug;4(8):1062-8. Epub 2006 Jul 14.

PMID:
16844421
7.

Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents.

Kim CH, Um SH, Seo YS, Jung JY, Kim JD, Yim HJ, Keum B, Kim YS, Jeen YT, Lee HS, Chun HJ, Kim CD, Ryu HS.

J Gastroenterol Hepatol. 2012 Oct;27(10):1589-95. doi: 10.1111/j.1440-1746.2012.07167.x.

PMID:
22554121
8.

Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis.

Rinaldi L, Nascimbeni F, Giordano M, Masetti C, Guerrera B, Amelia A, Fascione MC, Ballestri S, Romagnoli D, Zampino R, Nevola R, Baldelli E, Iuliano N, Rosato V, Lonardo A, Adinolfi LE.

World J Gastroenterol. 2017 Feb 28;23(8):1458-1468. doi: 10.3748/wjg.v23.i8.1458.

9.

Increased circulating endocan in patients with cirrhosis: relation to bacterial infection and severity of disease.

Zuwala-Jagiello J, Simon K, Kukla M, Murawska-Cialowicz E, Gorka-Dynysiewicz J, Grzebyk E, Pazgan-Simon M.

J Physiol Pharmacol. 2017 Apr;68(2):273-282.

10.

Incidence of hepatocellular carcinoma in outpatients with cirrhosis in Brazil: A 10-year retrospective cohort study.

Appel-da-Silva MC, Miozzo SA, Dossin IA, Tovo CV, Branco F, de Mattos AA.

World J Gastroenterol. 2016 Dec 14;22(46):10219-10225. doi: 10.3748/wjg.v22.i46.10219.

11.

Epidemiology of HCC in Brazil: incidence and risk factors in a ten-year cohort.

Paranaguá-Vezozzo DC, Ono SK, Alvarado-Mora MV, Farias AQ, Cunha-Silva M, França JI, Alves VA, Sherman M, Carrilho FJ.

Ann Hepatol. 2014 Jul-Aug;13(4):386-93.

12.

Clinical characteristics and outcome of hepatocellular carcinoma in alcohol related and cryptogenic cirrhosis: a prospective study.

Siriwardana RC, Niriella MA, Dassanayake AS, Liyanage C, Gunathilaka B, Jayathunge S, de Silva HJ.

Hepatobiliary Pancreat Dis Int. 2015 Aug;14(4):401-5.

PMID:
26256085
13.

Prognostic significance of serum galectin-3 levels in patients with hepatocellular cancer and chronic viral hepatitis.

Ulu M, Alacacioglu A, Yuksel E, Pamukk BO, Bozkaya G, Ari A, Yuksel A, Sop G, Alacacioglu I.

Saudi J Gastroenterol. 2015 Jan-Feb;21(1):47-50. doi: 10.4103/1319-3767.151228.

14.

Clinical outcomes of lamivudine-adefovir therapy in chronic hepatitis B cirrhosis.

Lim SG, Aung MO, Mak B, Sutedja D, Lee YM, Lee GH, Fernandes M, Low HC, Lai V, Dan YY.

J Clin Gastroenterol. 2011 Oct;45(9):818-23. doi: 10.1097/MCG.0b013e318214ab5d.

PMID:
21921845
15.

Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts the risk of HBV-related liver cancer development.

Kim SU, Heo JY, Kim BK, Park JY, Kim DY, Han KH, Ahn SH, Kim HS.

Liver Int. 2017 Jun;37(6):879-887. doi: 10.1111/liv.13341. Epub 2016 Dec 28.

PMID:
27973711
16.

Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease.

Wong CR, Njei B, Nguyen MH, Nguyen A, Lim JK.

Aliment Pharmacol Ther. 2017 Dec;46(11-12):1061-1069. doi: 10.1111/apt.14342. Epub 2017 Sep 28.

PMID:
28960360
17.

PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis.

Guyot E, Sutton A, Rufat P, Laguillier C, Mansouri A, Moreau R, Ganne-Carrié N, Beaugrand M, Charnaux N, Trinchet JC, Nahon P.

J Hepatol. 2013 Feb;58(2):312-8. doi: 10.1016/j.jhep.2012.09.036. Epub 2012 Oct 13.

PMID:
23069476
18.

Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy.

Pompili M, Rapaccini GL, Covino M, Pignataro G, Caturelli E, Siena DA, Villani MR, Cedrone A, Gasbarrini G.

Cancer. 2001 Jul 1;92(1):126-35.

PMID:
11443618
19.

Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.

Durazo FA, Blatt LM, Corey WG, Lin JH, Han S, Saab S, Busuttil RW, Tong MJ.

J Gastroenterol Hepatol. 2008 Oct;23(10):1541-8. doi: 10.1111/j.1440-1746.2008.05395.x. Epub 2008 Apr 19.

PMID:
18422961
20.

Hepatocellular carcinoma in cirrhotic versus noncirrhotic livers: results from a large cohort in the Netherlands.

van Meer S, van Erpecum KJ, Sprengers D, Coenraad MJ, Klümpen HJ, Jansen PL, IJzermans JN, Verheij J, van Nieuwkerk CM, Siersema PD, de Man RA.

Eur J Gastroenterol Hepatol. 2016 Mar;28(3):352-9. doi: 10.1097/MEG.0000000000000527.

PMID:
26629867

Supplemental Content

Support Center